Chromosome 17q23.1-q23.2 deletion syndrome with severe pulmonary hypertension in neonates: two case reports and literature review Authors: Xiaojiao Wu, Yanyan Cao, Jiancheng Jiao, Junchen Fang, Yudong Zhang, Li Ma Published: 2026 ABSTRACT AbstractBackgroundChromosome 17q23.1-q23.2 deletion syndrome is a rare genetic disorder characterized by various congenital defects, including microcephaly, heart and lung defects, limb abnormalities, and mild-to-severe developmental delay. Respiratory distress and severe pulmonary hypertension (PH) are possible initial symptoms.Case presentationWe report two cases of full-term neonates with respiratory distress presenting shortly after birth. They both presented with severe PH in the early postnatal period, with oxygenation indices exceeding 70. Their symptoms were temporarily relieved with comprehensive treatment but PH either persisted into, or reappeared in infancy. Case 1 had an anomalous origin of the right upper lobe bronchus on chest computed tomography (CT) imaging, while Case 2 had an atrial septal defect and cor triatriatum sinister on echocardiography. Case 2 also exhibited bilateral inner ear malformations and bilateral irregularities in the morphology of the auditory ossicles on temporal bone CT imaging. Whole-exome sequencing revealed a 2.0-2.3 Mb de novo heterozygous deletion at 17q23.1-q23.2 encompassing T-box transcription factor 2 and 4 genes in both infants, which were confirmed by quantitative real-time PCR. Despite receiving intensive care, they succumbed to irreversible PH and respiratory and heart failure, with one passing away at 3 months and the other at 20 months of age.ConclusionsThis is the first report of two cases of chromosome 17q23.1-q23.2 deletion syndrome diagnosed after birth in China, both associated with intractable PH, expanding the current clinical phenotype spectrum of this disorder.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12887-026-06839-x.Keywords: Chromosome 17q23.1-q23.2 deletion, Pulmonary hypertension, T-box transcription factor 2, T-box transcription factor 4, Genetics Background Chromosome 17q23.1-q23.2 deletion syndrome (OMIM 613355) is a genetic disorder characterized by multiple congenital anomalies involving the heart, lungs, and limbs. It is often accompanied by developmental delay. In 2010, chromosome 17q23.1-q23.2 deletion syndrome was first described in seven patients with low birth weight, microcephaly, heart defects, hand and foot anomalies, and hearing loss [1]. In the same year, Alvarado et al. [2] identified a 2.2 Mb 17q23.1-q23.2 deletion with congenital clubfoot in a sibling. In 2013, Kerstjens-Frederikse et al. [3] described the association between mutations or deletions in T-box transcription factor 4 gene (TBX4) and pediatric pulmonary arterial hypertension (PAH). Subsequently, several patients with this syndrome encompassing TBX4 deletion presented with neonatal or childhood-onset of pulmonary hypertension (PH) and lethal lung developmental disorders were reported [3–5]. To date, no more than 40 cases have been reported worldwide, with only one report on prenatal diagnosis in China [6]. Most cases are sporadic, and the morbidity is unknown. Herein, we reported two neonates with deletions in 17q23.1-q23.2, including TBX4 and T-box transcription factor 2 (TBX2) gene, who presented with severe and persistent PH during the neonatal and infancy periods. We also reviewed the available cases to explore the correlation between genetic factors and clinical manifestations. Using “17q23.1-q23.2,” “TBX4,” and “TBX2” as keywords, relevant information about 17q23.1-q23.2 deletion syndrome was searched at PubMed (until July 2024). We also searched the public database DECIPHER v11.27 using the following terms: grch37:17:57600001–61,100,000. Our aim was to increase the clinician’s understanding of the disease and prevent missed diagnosis when encountering similar cases. Case presentation Case 1 A female infant was born at 38 weeks by cesarean section to a gravidity 5 and parity 3 mother with a history of two instances of embryonic development arrest. Her birth weight was 3.07 kg (> 25th percentile on Girls Growth Chart of World Health Organization), body length was 57 cm (> 50th percentile), and head circumference was 35 cm (> 50th percentile). The parents were not consanguineous. The infant had no history of asphyxia at birth. Ten minutes after birth, she began to grunt and developed dyspnea unresponsive to noninvasive positive pressure ventilation. After 3 h, the infant was transferred to our hospital. No apparent abnormalities were observed on admission. Chest radiography revealed a right-sided pneumothorax (Fig.S1a). Echocardiography revealed an enlarged right heart with a patent foramen ovale (PFO) and patent ductus arteriosus (PDA) (approximately 6 mm wide). The pulmonary arterial pressure was estimated at 51 mmHg according to the velocity of tricuspid regurgitation (Fig.S2a). Shortly after admission, the infant was intubated on 100% oxygen with pulse oxygen saturation (SpO2) < 65% and treated with an intercostal chest drain, surfactant, and inhaled nitric oxide (iNO), starting at 20 ppm. Twenty hours after birth, her condition failed to improve, with SpO2 <70% and an oxygenation index (OI) of 77. Echocardiography revealed severe PAH (estimated 83 mmHg) and a complete right to left shunt via ductus arteriosus. Other treatments including the administration of oral sildenafil, continuous intravenous infusion of treprostinil, and multiple vasoactive agents comprising dopamine, adrenaline, and norepinephrine were provided. Thirty hours after birth, SpO2 of the infant gradually increased to > 85% and the OI decreased to 18. On the 3th day after birth, SpO2 increased to > 90%, partial pressure of oxygen (PaO2) increased to > 50 mmHg, and the OI decreased to 6. On the 10th day after birth, her oxygenation improved and SpO2 remained above 90%. Echocardiography showed change of shunt to bidirectional, indicating mild improvement in PAH. iNO and treprostinil were gradually weaned, and she was extubated and switched to noninvasive assisted ventilation. Ophthalmological examination suggested binocular retinopathy. At 24 days of age, the infant underwent whole-exome sequencing (WES) due to an atypical course of persistent pulmonary hypertension of the newborn (PPHN). Thirty days after birth, the infant was reintubated owing to recurrent desaturation and administered oral bosentan and sildenafil. iNO and continuous intravenous treprostinil were re-administered. Echocardiography revealed persistent PFO, PDA and PAH. Contrast-enhanced cardiac computed tomography (CT) revealed widened main pulmonary artery. At 48 days of age, whole-exome sequencing revealed a de novo heterozygous 2.30 Mb deletion at 17q23.1-q23.2 (chr17:58091640–60347046, hg19) containing the entire TBX4 and TBX2, which were confirmed by quantitative real-time PCR (qPCR). Chest CT suggested an abnormal origin in the anterior segment of the right upper lobe bronchus (Fig. 1a). At the age of 73 days, the infant was discharged with oral sildenafilon, bosentan and home oxygen therapy (fraction of inspired O2 (FiO2) 40%, SpO2 90–95%). She was still mildly dyspneic, with a respiratory rate of 40–50 breaths per minute. Full oral feeding was achieved on discharge. Weight on discharge was 4.35 kg. She continued to have intermittent episodes of hypoxia at home despite supplemental oxygen. Taking into account the genetic testing results and the potential poor prognosis, palliative care was provided for the infant. At 3 months of age, she died of hypoxic respiratory and heart failure due to chronic PH. The imaging information of patients. a Chest computed tomography (CT) of Case 1 . a1. Chest CT scan showing increased lung markings; a2. Three-Dimensional chest CT demonstrating the anterior segment bronchus of the upper lobe of the right lung originating from the posterior wall of the right main bronchus under the carina and a thinner initial part. b Contrast-enhanced cardiac CT of Case 2. Figure 1b1 and b2 both demonstrate the left coronary artery originated at a higher position, emerging from the upper edge of left coronary sinus. c Temporal bone CT of Case 2. Figure 1c1shows enlarged vestibules bilaterally and absence of bilateral horizontal semicircular canals; Fig. 1c2 shows irregular shape of the right ossicles Case 2 The male infant born at 39+ 3 weeks of gestation was the first child of non-consanguineous parents. His birth weight was 3.5 kg (> 50th percentile on Boys Growth Chart of World Health Organization), body length was 48 cm (< 25th percentile), and head circumference was 33 cm (15th percentile). The infant had Apgar scores of 10 at both 1 and 5-minutes. He developed cyanosis and dyspnea 1 h after birth. Emergency endotracheal intubation was performed and mechanical ventilation was subsequently initiated. He was transferred to our hospital at 5 h after birth due to the critical condition. On admission, physical examination revealed that the auricular areas of both ears were curled and the ears were asymmetrical. The lower limbs were slightly short, with a disproportionately long torso. Although he was intubated with the FiO2 of 100%, SpO2 remained low (83%) and OI was 70. Echocardiography revealed a PDA (approximately 3.1 mm wide), PFO, and severe PAH (estimated 70 mmHg according to the velocity of tricuspid regurgitation) (Fig. S2b). Chest radiography showed a right-sided and left lower lung pneumothorax (Fig. S1b). The infant was treated with iNO at 20 ppm and oral sildenafil, continuous intravenous treprostinil, and multiple vasoactive agents. After 19 h of treatment, SpO2 of the infant gradually increased to > 90%, PaO2 increased to > 60mmHg, and OI decreased to 16. At 9 days of age, the infant was extubated and switched to noninvasive assisted ventilation. At 18 days of age, echocardiography revealed an atrial septal defect (ASD) and no obvious PAH. Chest CT did not reveal significant bronchial or pulmonary dysplasia. Contrast-enhanced cardiac CT showed a widened main pulmonary artery and a left coronary artery that arose from the upper edge of left coronary sinus (Fig. 1b). Temporal bone CT showed bilateral inner ear malformations, increased density of the mastoid tympanic chambers, and bilateral irregularities in the morphology of the auditory ossicles (Fig. 1c). Moreover, the infant did not pass hearing screening. WES was performed at 21 days of age to evaluate the etiology based on these phenotypes. At 38 days after birth, WES identified a de novo heterozygous 2.05 Mb deletion at 17q23.1-q23.2 (chr17:58297010–60351497, hg19) containing the entire TBX4 and TBX2, which were confirmed by qPCR. At 39 days of age, echocardiography revealed ASD, cor triatriatum sinister (without obstruction) and no PAH. At 48 days of age, the infant reached full oral feeding, was discharged home with oral sildenafil and home oxygen therapy (FiO2 25%, SpO2 92–96%). He was still having mild dyspnea, with a respiratory rate of 40–50 breaths per minute. The weight on discharge was 4.28 kg. At the age of three months, echocardiographic revealed ASD (4.6 mm), cor triatriatum sinister and PAH (estimated 25mmHg). Consequently, the infant underwent a correction surgery of cor triatriatum and ASD. Postoperative echocardiography did not reveal any signs of PAH. However, the infant was readmitted to the pediatric intensive care unit twice from 4 to 7 months of age for severe pneumonia, respiratory failure, and heart failure. Echocardiography revealed reoccurred PAH (estimated 56mmHg) and the infant underwent oxygen therapy again. Given the repeated deterioration of the infant’s condition and the results of genetic testing, the parents opted for palliative treatment at home. At 20 months of age, he died of hypoxic respiratory and heart failure due to chronic PH. Literature review We have identified 35 reported similar cases. From PubMed, we identified 27 patients with 17q23.1-q23.2 deletion syndrome [1–9]. From DECIPHER v11.27, we identified 8 patients (DECIPHER ID: 249153, 249237, 250379, 357777, 401680, 307191, 280678, 276114), whose deletion regions overlapped with the syndrome. In the 35 previously reported cases, the deletions described were between 1.1 Mb and 2.8 Mb (Fig. 2), 95% (19/20) of which were de novo (Table S1). Among these, two fetuses were terminated from pregnancy after prenatal diagnosis [6, 8]. Overview of the deletions covering the 17q23.1-q23.2 region in previously reported patients (patients 1–23), the cases from the DECIPHER database (patients 28–35), and the patients described in this article (patients 26 and 27). The genes TBX2 and TBX4 are shown as red boxes A total of 27 cases had detailed clinical data (including our two cases and 25 postnatal cases reported in the articles) (Table 1) [1–5, 7–9]. Most were term infants (14/21, 67%), with the exception of seven born between 32 and 36 weeks. Microcephaly was present in 50% (7/14). Eye anomalies were present in seven cases, and hearing anomalies were noted in five cases. Almost 71% (12/17) of the patients had abnormal echocardiography findings. Musculoskeletal abnormalities were reported in 67% (14/21) of the cases, four of which had small patella syndrome (SPS, OMIM 147891) [1, 5, 7]. Among the 27 cases, 75% (18/24) had PH, and most presented with respiratory distress as the first symptom. Eleven cases presented with persistent PH, of which 91% (10/11) were neonatal onset and one was infancy onset with PH persisting into youth [5]. Among the PH patients, six underwent extracorporeal membrane oxygenation (ECMO) due to severe, persistent PH [4, 5, 8, 9]. Among the 27 cases, ten underwent autopsy or lung biopsy, seven of which were found with lethal lung disorders, including acinar dysplasia of the lungs and congenital alveolar dysplasia. Eleven patients experienced early death due to cardiorespiratory failure, 91% (10/11) of whom had persistent PH, and the rest one was not described. Among 13 survivors, only three had PH, and none had lethal lung developmental disorders. There was a notable prevalence of developmental delays, with a particular impact on language development. Table 1Clinical features of cases with 17q23.1-q23.2 deletionsPatient number (Ref)GenderGA (weeks)SGAInitial symptomOnset of PHPHTreatmentLLDDsLung biopsy/autopsyFindings of echocardiographyMusculoskeletalSPSMicrocephalyDevelopmental delaysHearing lossEyesOutcome1[1]F36w-N/AN/A-N/AN/A++(PDA)--++++(chalazion)survived2[1]F36w+N/AN/A-N/AN/A-+(ASD)--++-+ (left-sided esotropia)survived3[1]Mfull term-respiratory distressN/A+N/AN/A--++++--survived4[1]Ffull term+N/Ainfancy+ (persistent)N/AN/A-+(PDA)++-+++ (bilateral esotropia)survived5[1]F32w-N/AN/AN/AN/AN/A-+(PDA/PFO)+-++-+ (retinopathy of prematurity)survived6[1]Ffull term+N/AN/AN/AN/AN/A+----+-+survived7[1]F36w-N/Aneonatal period+N/AN/A-+(ASD)+-++--survived8[7]Ffull term-N/AN/A-N/AN/A----++++ (alternating strabismus and slight hypermetropia)survived9[7]Mfull term-N/AN/A-N/AN/A---++++-survived10[3]MN/AN/AN/Achildhood+N/AN/A-N/A+N/AN/AN/AN/AN/AN/A11[3]MN/AN/AN/Achildhood+N/AN/A-N/A+N/AN/AN/AN/AN/AN/A12[3]MN/AN/AN/Achildhood+N/AN/A-N/A+N/AN/AN/AN/AN/AN/A13[5]M36w+N/Aneonatal period+ (persistent)iNO, ECMO, phosphodiesterase 5 inhibitor++N/AN/AN/AN/AN/AN/AN/Adied after 5 months14[5]F36w-N/Aneonatal period+ (persistent)iNO, phosphodiesterase 5 inhibitor, endothelin receptor antagonistN/A-+(ASD)+-N/AN/AN/AN/Asurvived15[5]F40wN/AN/Achildhood+ (persistent)phosphodiesterase 5 inhibitor, treprostinilN/A-+(PDA)+-N/AN/AN/AN/Adied after 29 years16[5]F40wN/AN/Aneonatal period+ (persistent)iNO, ECMO, phosphodiesterase 5 inhibitor, treprostinil, epoprostenol, calcium channel blockerN/A-+(PDA/ASD/VSD)++N/AN/AN/AN/Asurvived17[4]M33w-severe hypoxia, hypotensionneonatal period+ (persistent)surfactant, iNO, ECMO+(AcDys)++(PFO)+N/A-N/AN/AN/Adied after 10 days18[8]F38wN/AN/AN/AN/AN/A+(AcDys)+N/AN/AN/AN/AN/AN/AN/Adied19[8]F40w+respiratory failureneonatal period+ (persistent)N/A+(AcDys)++(ASD)N/AN/AN/AN/AN/AN/Adied after 30 min20[8]Mfull term-severe hypoxia and respiratory distressneonatal period+ (persistent)iNO, ECMO, sildenafil, bosentan-+N/AN/AN/AN/AN/AN/AN/Adied after 10 weeks21[8]F40w-respiratory distress with refractory hypoxemianeonatal period+ (persistent)N/A++N/AN/AN/A-N/AN/AN/Adied after 24 h22[8]M33w-refractory hypoxemia and hypotensionneonatal period+ (persistent)iNO, ECMO+(AcDys)+N/A-N/A-N/AN/AN/Adied after 10 days23[9]M41w-respiratory distress and peripheral cyanosis, accompanied by low saturationneonatal period+ (persistent)surfactant, iNO, ECMO, epoprostenol, adrenaline catecholamine+(CAD)+-N/AN/AN/A+N/AN/Adied after 27 days24[2]MN/AN/AN/AN/AN/AN/AN/AN/AN/A+-N/A+N/AN/Asurvived25[2]FN/AN/AN/AN/AN/AN/AN/AN/AN/A+-N/A+N/AN/Asurvived26F38w-grunt and dyspneaneonatal period+ (persistent)surfactant, iNO, sildenafil, treprostinil, multiple vasoactive agents, bosentanN/A-+(PDA/PFO)---+-+died after 3 months27M39w-cyanosis and dyspneaneonatal period+ (persistent)surfactant, iNO, sildenafil, treprostinil, multiple vasoactive agentsN/A-+ (PDA/PFO/ASD/cortriatriatum sinister)+---+-died after 20 monthsAbbreviations: +, feature present; -, feature absent, F Female, M Male, GA Gestational age, SGA Small for gestational age, PH Pulmonary hypertension, LLDDs Lethal lung developmental disorders, AcDys Acinar dysplasia of the lungs, CAD Congenital alveolar dysplasia, PDA Patent ductus arteriosus, ASD Atrial septal defect, PFO Patent foramen ovale, VSD Ventricular septal defect, SPS Small patella syndrome, CNVs Copy number variants, iNO Inhalation of nitric oxide, EMCO Extracorporeal membrane oxygenation, N/A Not available Clinical features of cases with 17q23.1-q23.2 deletions Abbreviations: +, feature present; -, feature absent, F Female, M Male, GA Gestational age, SGA Small for gestational age, PH Pulmonary hypertension, LLDDs Lethal lung developmental disorders, AcDys Acinar dysplasia of the lungs, CAD Congenital alveolar dysplasia, PDA Patent ductus arteriosus, ASD Atrial septal defect, PFO Patent foramen ovale, VSD Ventricular septal defect, SPS Small patella syndrome, CNVs Copy number variants, iNO Inhalation of nitric oxide, EMCO Extracorporeal membrane oxygenation, N/A Not available Discussion Deletions of chromosome 17q23.1-q23.2 encompass 26 protein-coding genes, including the critical genes TBX2 (chr17:59477204–59486827, hg19) and TBX4 (chr17:59529783–59562471, hg19) [5, 8]. Both TBX2 and TBX4 belong to the T-box family of transcription factors, which have a significant impact on embryonic development regulation in vertebrates [10]. Some studies have shown that variants in TBX4 are associated with respiratory and skeletal illnesses [3, 5, 11]. TBX2 is important in cardiac development [12]. With the exception of patient 23 [9] and two cases with unknown details, all other reported patients possessed deletions that encompassed both TBX4 and TBX2 (Fig. 2), presenting with varying lung or heart abnormalities. In the two infants we reported, Case 1 showed abnormal origin in the anterior segment of the right upper lobe bronchus from chest CT, while Case 2 demonstrated cardiac abnormalities. Among the previously reported cases, 67% had musculoskeletal abnormalities, and four patients had SPS [1, 5, 7]. In 2004, Bongers et al. [11] identified TBX4 defect as a possible genetic cause of SPS. Our patients did not present with the characteristics of SPS, but Case 2 demonstrated skeletal dysplasia of the lower limbs. Eye or hearing abnormalities were also found in our two cases. Case 1 had binocular retinopathy, and Case 2 exhibited abnormal temporal bone CT findings that had not been previously reported. Eighteen patients (18/24, 75%) including our two cases presented with PH. The varying clinical phenotypes may be related to the different sizes of the deletion at 17q23.1-q23.2 and the involvement of other neighboring genes (Fig. 2). PH is a disease spectrum that encompasses a variety of cardiovascular and pulmonary diseases [13]. PPHN as a subgroup of PAH [14], is generally secondary to reversible causes such as respiratory distress syndrome, meconium aspiration syndrome, pneumonia, or perinatal asphyxia, which can be generally resolved during the first few days. However, other causes may also present with PPHN as the initial manifestation. Cases with irreversible PPHN in neonates maybe associated with genetic developmental lung disorders [15, 16]. In the 2022 PH guidelines, newly recognized genetic developmental lung disorders including TBX4-mutation-related was categorized as PH group 3, which is not exactly the same as PAH (PH group 1) in pathophysiology [13]. The two cases we reported both had poor response to the routine targeted treatment for respiratory failure and PPHN. The OI was extremely high and met ECMO criteria. Multiple pulmonary vasodilators accompanied with vasoactive agents were needed to maintain the oxygenation and repeated echocardiography indicated the persistent existence of PH. Although response was poor, these hemodynamic stabilization treatments provided an opportunitiy to work-up for genetic causes. We speculate that our two cases could have experienced PPHN at birth. Whereas, the unusual severe manifestation and PH in their remote infancy should be mainly due to the genetic developmental lung disease [13]. Unfortunately, we did not have a lung biopsy and pathologic autopsy, and hence it is difficult to truly identify whether pulmonary or pulmonary arterial involved hypertension was the cause of the infants’ demise. Some studies have suggested that mutations or deletions in TBX4 can be responsible for PH [3, 5], but the mechanism is still unclear. TBX4 is highly expressed in the lung mesenchyme [17, 18]. Deletion of TBX4 expression in the lung mesenchyme of mouse embryos severely impairs lung branching morphology, possibly due to the suppression of fibroblast growth factor 10 (FGF10) expression in embryonic lung fibroblasts, which disrupted reciprocal signaling between pulmonary mesenchymal and epithelial cells during lung morphogenesis [18]. Additionally, reducing TBX4 levels decreases phospho-Smad1/5 levels in embryonic lung fibroblasts [19]. Reduced levels of FGF10 and p-Smad1/5 can inhibit the activation of bone morphogenetic protein/transforming growth factor β-Smad signaling pathway, which is crucial for regulating the proliferation and apoptosis of pulmonary artery smooth muscle and endothelial cells. In addition, TBX4 deletion decreases Tie2 and Kruppel-like factor 4 levels, which can result in endothelial dysfunction and subsequently cause pulmonary vascular remodeling associated with PH [17]. Two studies [5, 20] described the histopathological findings in patients with TBX4 mutations, revealing different degrees of remodeling of pulmonary artery wall, as well as some distal tracheal dysplasia, which may be the anatomical basis leading to severe and persistent PH. Furthermore, prenatal ultrasound may be a useful tool for the early recognition of chromosome 17q23.1-q23.2 deletion syndrome. Yao et al. [6] described a fetus diagnosed with primary bilateral lung hypoplasia using echocardiography. Further array-comparative genomic hybridization revealed a 2.14 Mb deletion at 17q23.1-q23.2 by cord blood. The parents opted to terminate the pregnancy after receiving genetic counseling. Karolak et al. [8] documented a 32-week-old fetus with a 2.25 Mb deletion at 17q23.1-q23.2. The fetus presented with severe PAH on prenatal ultrasonography and alveolar dysplasia of the lungs through autopsy. Consequently, genetic testing and prompt counseling are crucial when prenatal ultrasound findings indicate pulmonary hypoplasia. In this review, we describe in detail two unusual full-term neonates with the deletion of 17q23.1-q23.2 presented with severe PH shortly after birth. We recommend further work-up for genetic causes when PH is difficult to resolve. If a gene panel for PH is utilized, it is imperative to incorporate analyses for detecting deletions to avoid missing the 17q23.1-q23.2 region. The patients carrying 17q23.1-q23.2 deletion encompassing TBX4 and TBX2 may exhibit severe neonatal onset PH, necessitating an extended persistent targeted therapy beyond neonatal period and often indicate a poor prognosis. Moreover, our cases present additional feature that have never been described previously, which expanded the clinical phenotype spectrum of the syndrome. Supplementary Information Supplementary Material 1 Acknowledgements We’d like to express our sincere gratitude to the patients and their parents for their invaluable cooperation throughout the course of this study. Additionally, we would like to extend our appreciation to Editage (www.editage.cn) for their professional English language editing services. Abbreviations Atrial septal defect Computed tomography Extracorporeal membrane oxygenation Fibroblast growth factor 10 Fraction of inspiration O2 Human Genome version 19 Inhaled nitric oxide Oxygenation index Online Mendelian Inheritance in Man Pulmonary arterial hypertension Patent ductus arteriosus Patent foramen ovale Pulmonary hypertension Persistent pulmonary hypertension of the newborn Quantitative real-time PCR Small patella syndrome Pulse oxygen saturation Authors’ contributions XW and YC played key roles in drafting the manuscript and conducting the analytical work. JJ, YZ, and JF were instrumental in managing patient follow-ups and data collection. LM provided a critical review of the paper and offered insightful revisions to the analytical methods. Each author has made significant contributions to this article and has given their approval to the final version submitted for publication. Funding This study was supported by the Government Funded Clinical Medicine Excellent Talent Training Project (ZF2022034; ZF2023209). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate The studies involving human participants were reviewed and approved by Ethics Committee of Institute of Pediatric Research, Children’s Hospital of Hebei Province. Informed consent was obtained from parents of the participants included in this study. Consent for publication Written informed consent was obtained from the parents for publication of this case report. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xiaojiao Wu and Yanyan Cao contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement No datasets were generated or analysed during the current study.